Sling Therapeutics Announces Publication Demonstrating Attenuation of Pathologic Bone Marrow Activity with Linsitinib in a Mouse Model of Thyroid Eye Disease
- Monday, September 25, 2023, 7:00
- Finance
- Add a comment
– Linsitinib inhibited the formation of CD4+ T-cells in bone marrow, which are upregulated and clinically relevant in Thyroid Eye Disease (TED) – – Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for treatment of active, moderate to severe TED will provide clinical…
About the Author
adminasapcorp has written 39023 stories on this site.